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Abstract 
Background: Organizing pneumonia is a reaction pattern and an inflammatory response to acute lung injuries, and 
is characterized by intraluminal plugs of granulation tissue in distal airspaces. In contrast to other fibrotic pulmonary 
diseases, organizing pneumonia is generally responsive to corticosteroids. However, some patients do not respond to 
treatment, leading to respiratory failure and potentially death (up to 15 % of patients). In order to devise new thera-
peutic strategies, a better understanding of the disease’s pathomechanisms is warranted. We previously generated a 
mouse model overexpressing CCL2, which generates organizing pneumonia-like changes, morphologically compara-
ble to human patients. In this study, we investigated whether the histopathological similarities of human and murine 
pulmonary organizing pneumonia lesions also involve similar molecular pathways.
Methods: We analyzed the similarities and differences of fibrosis-associated gene expression in individual compart-
ments from patients with organizing pneumonia and transgenic (CCL2) mice using laser-assisted microdissection, 
real-time PCR and immunohistochemistry.
Results: Gene expression profiling of human and murine organizing pneumonia lesions showed in part comparable 
expression levels of pivotal genes, notably of TGFB1/Tgfb1, TIMP1/Timp1, TIMP2/Timp2, COL3A1/Col3a1, CXCL12/
Cxcl12, MMP2/Mmp2 and IL6/Il6. Hence, the transgenic CCL2 mouse model shows not only pathogenomic and mor-
phological features of human organizing pneumonia but also a similar inflammatory profile.
Conclusions: We suggest that the CCL2-overexpressing transgenic mouse model (CCL2 Tg mice) is suitable for fur-
ther investigation of fibrotic pulmonary remodeling, particularly of organizing pneumonia pathogenesis and for the 
search for novel therapeutic strategies.
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Background
Organizing pneumonia (OP) is a reaction pattern and an 
inflammatory response towards acute lung injuries. Orig-
inally, OP was described by Davison and coworkers in 
1983 and referred to as “bronchiolitis obliterans organiz-
ing pneumonia” (BOOP) [1]. Nowadays, in order to avoid 
confusion with the distinct airway disease bronchiolitis 
obliterans (BO), the term OP is preferred.
In principle, there are two manifestations of OP: (1) 
cryptogenic organizing pneumonia (COP) of unknown 
cause [2] and (2) secondary organizing pneumonia 
(SOP), based on a known cause, e.g. infections (bacte-
rial, viral, fungal or parasitic), drugs (antibiotics, antiepi-
leptics, immunomodulators), inflammatory diseases like 
connective tissue disease, vasculitis or following lung/
bone marrow transplantation [3]. In general, OP is con-
sidered to be a non-specific, aberrant reparative response 
to a multitude of injurious stimuli.
Histomorphologically, OP is characterized by intralu-
minal plugs of granulation tissue (predominantly within 
the alveolar ducts and surrounding alveoli), with whorls 
of fibroblasts and activated myofibroblasts embedded 
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In contrast to other fibrotic lung diseases, like BO, OP 
is generally responsive to corticosteroids [4, 5] and the 
majority of patients with COP respond to this common 
therapy with rapid clinical, radiological and functional 
improvement. However, up to 15  % of patients do not 
respond to treatment at all and show a progressive dete-
rioration, leading to respiratory failure and, potentially, 
death [3, 5, 6]. Recognition of the underlying pathological 
mechanisms of OP, especially of its progressive variant, 
might help to identify those patients who will progress to 
respiratory failure [7]. Cell culture models are not suit-
able to recapitulate the complex remodeling mechanisms 
of OP. Therefore, animal models depicting human OP are 
needed to develop new therapeutic strategies. Among the 
animal models available, at least two limitations can be 
identified: firstly, they are dedicated to study airway oblit-
eration (OAR) rather than BOOP—or more precisely 
OP—and secondly, they do not depict either disease sat-
isfactorily [8].
In a previous study, we observed that transgenic mice 
overexpressing human CC chemokine ligand 2 (hCCL2) 
under control of the surfactant protein C promoter in 
type II alveolar epithelial cells (CCL2 Tg mice) responded 
to infectious challenge with Streptococcus pneumoniae 
(S. pneumoniae) with profound OP-like lesions involving 
the peripheral bronchioles and alveoli, particularly in the 
later resolving phase of bacterial pneumonia (day 7 post-
infection), therefore recapitulating OP manifestations 
morphologically comparable to those seen in human 
patients [9].
The initial trigger leading to OP is thought to be a cir-
cumscribed epithelial injury, which induces the death 
of pneumocytes and the formation of gaps in the basal 
lamina [3, 4]. Fibroblasts and inflammatory cells like 
lymphocytes, neutrophils and eosinophils then infiltrate 
the alveolar interstitium and form fibroinflammatory 
buds. This results in the formation of granulation tis-
sue, which then progresses into a network of polypoid 
plugs within the lumen of bronchioles, alveolar ducts 
and adjacent peribronchiolar alveoli [3–5]. The cells 
involved express proinflammatory factors which in turn 
attract more leukocytes and profibrotic progenitor cells 
and lead to deposition and remodeling of more extra-
cellular matrix (ECM) [10]. In human lungs, leukocytes 
and stroma cells within OP lesions express proinflam-
matory genes (e.g. interleukin 6/IL6), pivotal profi-
brotic signaling factors such as transforming growth 
factor-beta 1 (TGFB1) and downstream Sma and Mad-
related protein family members (SMADs) as well as 
profibrotic/antiangiogenic matricellular thrombospon-
din 1 (THBS1). Expression of these factors is generally 
associated with collagen production within pulmonary 
fibrotic lesions [10, 11]. Accumulation and persistence 
of collagen in the ECM are dependent on the expres-
sion of bone morphogenetic proteins (BMPs), matrix 
metalloproteinases (MMPs) and complementary tissue 
inhibitors of MMPs (TIMPs). Inflammatory cells also 
express protein tyrosine kinase 2 (PTK2), a cytoplasmic 
factor which contributes to the focal adhesions which 
form between cells and the adjacent ECM [10, 11]. 
Furthermore, stroma cell-secreted chemokine (C-X-C 
motif ) ligand 12 (CXCL12) and its leukocyte-derived 
chemokine (C-X-C motif ) receptor 4 (CXCR4) are over-
expressed, which indicates mobilization of CXCL12/
CXCR4-mediated leukocytes [10, 11].
In the present study, we investigated whether the his-
topathological pulmonary OP lesions in humans and 
mice share a similar, OP-related molecular phenotype, 
which in turn would identify CCL2 transgenic mice as a 
suitable humanized mouse model of OP, allowing future 
evaluation of OP-directed therapeutic strategies. Hence, 
we analyzed fibrosis-associated gene expression profiles 
from individual compartments of human and transgenic 
CCL2 mouse lungs.
Methods
Human specimens and study groups
OP represents a reaction pattern leading? Towards a 
variety of lung injuries, which manifests with a distinct 
and common morphology despite different underlying 
causes. Therefore, we investigated formalin-fixed and 
paraffin-embedded (FFPE) lung samples with organizing 
pneumonia (n =  5) from explanted native lungs of dif-
ferent clinical backgrounds, harvested during allogeneic 
lung transplantation and downsizing samples (n  =  6) 
from donor lungs, which were resected just before lung 
transplantation, as controls. The average age of patients 
(two women and three men) with OP at the time of trans-
plantation was 42.4  years (range 5.3–70.2  years). FFPE 
samples were retrieved from the archives of the Institute 
of Pathology, Hannover Medical School (Hannover, Ger-
many) and were handled anonymously according to the 
requirements of the local ethics committee (MHH ethics 
committee vote no. 2050-2013).
Human CCL2 transgenic mice
The murine FFPE lung tissue was obtained from the 
archives of the Department of Experimental Pneumol-
ogy (Hannover Medical School). The generation of the 
human CCL2 expressing mice was previously described 
[12]. Briefly cDNA encoding human MCP-I was inserted 
into the previously described SRF2T plasmid. Targeted 
expression of a dominant negative FGF receptor blocks 
branching morphogenesis and epithelial differentia-
tion of the mouse lung and microinjected into fertilized 
eggs [13].
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Adult mice derived from these eggs were infected 
with a Pneumolysin-producing clinical isolate of the 
S. pneumoniae as described in [12]. Both study groups 
comprised 8–12-week-old Balb/c mice. Briefly, a clini-
cal isolate of S. pneumoniae capsular group 19 strain 
EF3030 was cultivated in Todd-Hewitt broth (Difco) sup-
plemented with 0.1 % yeast extract to mid-log phase. Ali-
quots of bacterial suspensions were snap-frozen in liquid 
nitrogen and stored at −80 °C until further use. Bacterial 
numbers were quantified by plating of serial dilutions 
on sheep blood agar plates (BD Biosciences) followed by 
incubation of the plates at 37  °C/5  % CO2 for 18  h and 
subsequent determination of CFU.
Infection of CCL2 overexpressing and wild-type mice 
with S. pneumoniae was done using freshly prepared 
dilutions of thawed aliquots adjusted to ∼3 × 107 CFU/
mouse. Briefly, tracheas were exposed by surgical resec-
tion, and intratracheal instillation of the pneumococci 
was performed under stereomicroscopic control (MS 5; 
Leica) using a 26-gauge catheter (Abbocath) inserted into 
the trachea. After instillation, the neck wound was closed 
with sterile sutures as described in [12].
At 7  days post infection Wild-type and CCL2 over-
expressing mice were killed via an overdose of Isoflu-
rane. Subsequently, lungs were inflated in  situ with 
a prewarmed solution of Tissue-Tek (Sakura) kept at 
37  °C. Thereafter, the lungs were carefully removed and 
immersed in PBS-buffered formaldehyde solution (4.5 %, 
pH 7.0) for at least 24  h fixation at room temperature. 
Lung tissue samples were paraffin-embedded, and lung 
sections of 5  μm were stained with H&E and Elastica-
van-Gieson and examined histopathologically using a 
Zeiss Axiovert 200 M microscope.
The histopathological evaluation of transgenic mice 
overexpressing human CCL2 (n =  10) and correspond-
ing wild-type control mice (n = 10) was performed by an 
experienced lung pathologist (DJ) on H&E and Elastica 
van Gieson-stained sections. Notably, transgenic mice 
expressed CCL2 under the control of the surfactant pro-
tein C promoter. Therefore, human CCL2 is selectively 
expressed by type II alveolar epithelial cells, resulting in 
hCCL2-dependent alveolar accumulation of monocyte 
and lymphocyte subsets under baseline conditions, as 
characterized previously in detail [9, 12].
Laser‑assisted microdissection and RNA extraction
FFPE tissue sections of 5  µm thickness were mounted 
on a poly-l-lysine-coated membrane fixed onto a metal 
frame for laser-microdissection (MMI Molecular 
Machines Industries AG, Glattbrugg, Switzerland). After 
deparaffinization and hemalaun staining, non-obliterated 
bronchioles and OP lesions from human and murine lung 
tissue were isolated with the CellCut Plus system (MMI). 
The microdissected material was suspended directly into 
the adhesive cap with proteinase K buffer, incubated 
overnight and RNA was isolated with phenol/chloroform 
extraction according to our established procedure [14].
cDNA generation and real‑time PCR of CCL2 
and fibrosis‑associated genes
The total amount of extracted RNA was converted to 
cDNA by using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA, USA), 
following the manufacturer’s protocol. This cDNA was 
then preamplified with nonrandom PCR primers and 
PreAmp MasterMix (Applied Biosystems, Carlsbad, CA, 
USA) which results in a decrease of CT values by 14 PCR 
cycles [15]. For the subsequent quantitative real-time 
PCR (TaqMan 7500 Real-Time PCR system, Applied Bio-
systems, Carlsbad, CA, USA), the preamplified cDNA 
was mixed with TaqMan Gene Expression Master Mix 
and the individual TaqMan Gene Expression Assay. 
For verification of CCL2 overexpression, transcripts of 
human CCL2 as well as murine endogenous Ccl2 were 
evaluated.
A panel of fibrosis- and inflammation-associated 
murine and human genes selected on the basis of previ-
ous work was analyzed: Il6/IL6, Tgfb1/TGFB1, Thbs1/
THBS1, Smad1/SMAD1 and Smad3/SMAD3, Bmp4/
BMP4, bone morphogenetic protein receptor type-1b 
(Bmpr1b/BMPR1B), collagen type III, alpha 1 (Col3a1/
COL3A1), Mmp2/MMP2, Timp1/TIMP1 and Timp2/
TIMP2, Ptk2/PTK2, Cxcl12/CXCL12 and Cxcr4/CXCR4 
(Table 1) [10, 11]. The gene DNA-directed RNA polymer-
ase II subunit RPB1 (Polr2a/POLR2A) was used as an 
endogenous reference gene. For negative controls, cDNA 
was replaced by water.
Immunohistochemistry
Serially cut sections (1 µm) were deparaffinized and rehy-
drated with descending alcohol concentrations and then 
immunohistochemically stained for different inflamma-
tion- and fibrosis-associated targets using commercially 
available antibodies (Table 2) and a standard ABC proto-
col [10, 11].
Statistics
CT values were calculated by normalization to the mean 
expression of the reference gene (Polr2a/POLR2A) and 
converted into 2−ΔCT values with Microsoft office Excel 
2010 (Microsoft, Redmond, WA, USA). The statisti-
cal analysis was performed with GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA, USA) using the 
Mann–Whitney U test for comparison of wild-type and 
transgenic mice as well as the human OP lesions and nor-
mal airways from controls, and the Wilcoxon signed-rank 
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Table 1 Description of inflammation- and fibrosis-associated genes investigated in human (OP and control) lungs and in 
transgenic and nontransgenic mice





Bone morphogenetic protein 
4
BMP4 Bmp4 BMPs are a group of growth factors also known as cytokines and are 
part of the transforming growth factor beta superfamily. BMPs induce 
cartilage and bone formation
Bone morphogenetic protein 
receptor, type 1B
BMPR1B Bmpr1b On ligand binding, a receptor complex forms consisting of two type II 
and two type I transmembrane serine/threonine kinases. Type II recep-
tors phosphorylate and activate type I receptors which autophospho-
rylate, then bind and activate SMAD transcriptional regulators
Chemokine (C-C motif ) 
ligand 2
CCL2 Ccl2 This chemokine is a member of the CC subfamily which is characterized 
by two adjacent cysteine residues. This cytokine displays chemotactic 
activity for monocytes and basophils but not for neutrophils or eosino-
phils. It has been implicated in the pathogenesis of diseases character-
ized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and 
atherosclerosis. It binds to chemokine receptors CCR2 and CCR4
Collagen, type III, alpha 1 COL3A1 Col3a1 Collagen type III occurs in most soft connective tissues (skin, lung, uterus, 
intestine and the vascular system) along with type I collagen. Involved 
in the regulation of cortical development
Chemokine (C-X-C motif ) 
ligand 12
CXCL12 Cxcl12 Chemoattractant active on T-lymphocytes, monocytes, but not neu-
trophils. It functions as the ligand for the G protein-coupled receptor, 
chemokine (C-X-C motif ) receptor 4, and plays a role in many diverse 
cellular functions, including embryogenesis, immune surveillance, 
inflammation response, tissue homeostasis, and tumor growth and 
metastasis
Chemokine (C-X-C motif ) 
receptor 4
CXCR4 Cxcr4 Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal 
by increasing intracellular calcium ion levels and enhancing MAPK1/
MAPK3 activation. Acts as a receptor for extracellular ubiquitin; leading 
to enhanced intracellular calcium ions and reduced cellular cAMP levels
Interleukin 6 IL6 Il6 Cytokine that functions in inflammation and the maturation of B cells. In 
addition, it has been shown to be an endogenous pyrogen capable of 
inducing fever in people with autoimmune diseases or infections. The 
protein is primarily produced at sites of acute and chronic inflamma-
tion, where it is secreted into the serum and induces a transcriptional 
inflammatory response through interleukin 6 receptor alpha
Matrix metallopeptidase 2 MMP2 Mmp2 Ubiquitinous metalloproteinase that is involved in diverse functions such 
as remodeling of the vasculature, angiogenesis, tissue repair, tumor 
invasion, inflammation, and atherosclerotic plaque rupture. As well 
as degrading extracellular matrix proteins, it can also act on several 
non-matrix proteins such as big endothelin-1 and beta-type CGRP 
promoting vasoconstriction
Protein tyrosine kinase 2 PTK2 Ptk2 Non-receptor protein-tyrosine kinase that plays an essential role in regu-
lating cell migration, adhesion, spreading, reorganization of the actin 
cytoskeleton, formation and disassembly of focal adhesions and cell 
protrusions, cell cycle progression, cell proliferation and apoptosis
SMAD family member 1 SMAD1 Smad1 This protein mediates the signals of the bone morphogenetic proteins 
(BMPs), which are involved in a range of biological activities including 
cell growth, apoptosis, morphogenesis, development and immune 
responses. In response to BMP ligands, this protein can be phosphoryl-
ated and activated by the BMP receptor kinase, type I. The phospho-
rylated form of this protein forms a complex with SMAD4, which is 
important for its function in the transcription regulation
SMAD family member 3 SMAD3 Smad3 Receptor-regulated SMAD (R-SMAD) that is an intracellular signal trans-
ducer and transcriptional modulator activated by TGF-beta (transform-
ing growth factor) and is thought to play a role in the regulation of 
carcinogenesis
Transforming growth factor, 
beta 1
TGFB1 Tgfb1 Multifunctional protein that controls proliferation, differentiation and 
other functions in many cell types. Many cells synthesize TGFB1 and 
have specific receptors for it. It positively and negatively regulates many 
other growth factors. At low concentrations in concert with IL-6 and 
IL-21, it leads to expression of the IL-17 and IL-23 receptors, favoring 
differentiation to Th17 cells
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test to compare the respective compartment/lesions 
within the transgenic mice. Statistically significant differ-
ences between the different groups were assumed when p 
values were <0.05.
Results
Analysis of CCL2/Ccl2 expression levels in human und 
murine lung tissues
Gene expression levels of CCL2/Ccl2 were analyzed via 
quantitative PCR. As expected, CCL2 tg mice expressed 
human CCL2 in their lungs parenchyma, while the 
control group was negative. Moreover, CCL2 Tg mice 
expressed higher levels of human CCL2 than endog-
enous murine Ccl2 (Fig.  1a), while the development of 
OP correlated with the expression level in CCL2 Tg mice 
(Fig. 1b). In human lungs, the endogenous CCL2 was not 
significantly different in samples from OP lungs com-
pared to healthy controls (data not shown).
Histopathological manifestation of OP in transgenic mice
Consistent with previous reports [9], histopathologi-
cal evaluation of archived lung tissues from CCL2 Tg 
and WT mice showed that 50 % of CCL2 Tg mice devel-
oped OP after infection with S. pneumoniae, while con-
trol mice did not respond with OP after infection with S. 
pneumoniae (Fig. 2). However, it turned out that animals 
that developed OP show a higher expression of hCCL2 
compared to animals without OP lesions (Fig. 1b).
Deregulation of inflammation‑associated genes in OP 
lesions
Via isolation of OP lesions and non-affected airways 
using laser-microdissection and complementary immu-
nohistochemistry, gene expression profiles were analyzed 
in a compartment-specific manner.
CCL2 transgene expression was not directly linked 
to expression of inflammatory mediators. Both, CCL2 
Tg and WT mice exhibited similar levels of transcript 
expression of almost all factors under investigation in 
non-remodeled pulmonary compartments. However, an 
OP lesion-specific overexpression was found for Tgfb1, 
Cxcr4, Cxcl12, Thbs1, Timp1, Timp2 and Col3a1 (Figs. 3, 
4), while Bmp4 and its complementary receptor Bmpr1b 
were downregulated. Levels of Mmp2 and Ptk2 showed 
a trend towards higher levels in OP, but differences were 
only significant at the level of intra-individual compari-
son to non-remodeled lung tissue in CCL2 transgenic 
mice. Smad1, Smad3 and Il6 were expressed at similar 
Table 1 continued





Thrombospondin 1 THBS1 Thbs1 This protein is an adhesive glycoprotein that mediates cell-to-cell and 
cell-to-matrix interactions. It can bind to fibrinogen, fibronectin, 
laminin, type V collagen and integrins alpha-V/beta-1 and has been 
shown to play roles in platelet aggregation, angiogenesis, and tumori-
genesis
Tissue inhibitor  
of metalloproteinase 1
TIMP1 Timp1 Metalloproteinase inhibitor that functions by forming one to one com-
plexes with target metalloproteinases, such as collagenases, and irre-
versibly inactivates them by binding to their catalytic zinc cofactor. Acts 
on all MMPs, except on MMP14. Also functions as a growth factor that 
regulates cell differentiation, migration and cell death and activates 
cellular signaling cascades
Tissue inhibitor  
of metalloproteinase 2
TIMP2 Timp2 In addition to an inhibitory role against metalloproteinases, this protein 
has a unique role among TIMP family members in its ability to directly 
suppress the proliferation of endothelial cells. As a result, the encoded 
protein may be critical to the maintenance of tissue homeostasis by 
suppressing the proliferation of quiescent tissues in response to angio-
genic factors, and by inhibiting protease activity in tissues undergoing 
remodeling of the extracellular matrix
Information is taken from HUGO gene Nomenclature Committee, Uniprot and NCBI-Gene
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levels in CCL2 Tg and control mice and were not deregu-
lated in OP lesions. 
Although the overall expression levels in human lung 
tissue were in total higher than in murine lungs, laser-
microdissected OP lesions and non-remodeled bronchi-
oles displayed comparable levels of significance regarding 
fibrosis- and inflammation-associated genes. Genes like 
TGFB1, TIMP1, TIMP2, COL3A1, CXCL12 and MMP2 
were significantly upregulated in OP lesions from human 
lung explant tissue (Figs. 3, 4), while BMP4 and BMPR1B 
showed contrary results between OP lesions from human 
and mouse lungs. In murine OP lesions, these two genes 
were downregulated, whereas human OP lesions demon-
strated increased expression levels compared to controls. 
THBS1, CXCR4, PTK2 and IL6 were expressed at similar 
levels in human OP lesions and controls. While SMAD1 
Fig. 1 a mRNA expression of human CCL2 (hCCL2) versus murine Ccl2 (mCCL2) in murine lungs. Human CCL2 is only expressed in transgenic mice, 
but not in controls. The murine (endogenous) Ccl2 was expressed in both transgenic and nontransgenic animals. Log scale (y-axis). b Transgenic 
animals expressing hCCL2 divided into those with and without OP manifestation
Fig. 2 OP lesions stained by hematoxylin and eosin (a, d), and immunohistochemically against MMP2 (b, e) and IL6 (c, f) in transgenic mice (a–c) 
and in human OP lungs (d–f). Histopathologically, the organizing pneumonia pattern (arrows), which is characterized by excessive intraalveolar 
proliferations of granulation tissue, associated with lymphocytic pneumonitis in the surrounding lung tissue, is comparable in humans and mice. 
Scale bars correspond to 100 µm
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and SMAD3 were not upregulated in transgenic and 
control animals, SMAD1 showed an elevated expression 
level in human OP lesions, whereas SMAD3 was down-
regulated (Figs. 3, 4). Immunohistochemistry confirmed 
the mRNA expression results as summarized in Fig.  2 
and Table 3.
Discussion
The inflammatory microenvironment of OP in human 
and murine lungs is still not well understood. Previous 
analyses have for the most part focused on OP-related 
lung diseases, in particular BO (Tab. 4). In these studies, 
similarly to our present study, TGFB1/Tgfb1, TIMP1/
Timp1, COL3A1/Col3a1 and CXCL12/Cxcl12 were 
analyzed in human patients who suffered from BO fol-
lowing lung transplantation as well as in heterotopic 
tracheal transplantation (“BO-like”) and “IPF-like” bleo-
mycin mouse models (Table  4) [10, 16–21]. Here, we 
aimed to investigate which inflammation-related factors 
expressed in our OP mouse model are comparable with 
the corresponding results in human patients. Notably, 
in both OP mouse and human tissues from OP patients 
Fig. 3 Gene expression levels of the Tgfb1/TGFB1 cascade in murine OP lesions, compared to controls. TGFB1/Tgfb1, CXCL12/Cxcl12, TIMP1/Timp1, 
TIMP2/Timp2, COL3A1/Col3a1 and MMP2/Mmp2 show an OP lesion-specific overexpression in both human and murine lungs. In contrast, BMP4 
and BMPR1B were upregulated in human OP lesions, compared to controls, while in murine lungs both genes were downregulated. There was no 
significant difference in the expression level of IL6/Il6. Ctrl.—control(s)
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we found comparable expression levels of pivotal genes, 
such as TGFB1/Tgfb1, TIMP1/Timp1, TIMP2/Timp2, 
COL3A1/Col3a1, CXCL12/Cxcl12, MMP2/Mmp2 and 
IL6/Il6. These results allow us to conclude that the trans-
genic CCL2 mouse model not only shows pathogenomic, 
molecular and morphological features of human OP but 
also exhibits a similar inflammatory profile.
It has previously been shown that CCL2 Tg mice are 
prone to develop fibrotic pulmonary lesions in terms of 
OP, following bacterial infection [9]. In the current study, 
we showed that human CCL2 overexpression adds to the 
endogenous murine Ccl2 expression in CCL2 Tg mice. 
CCL2 is a major monocyte chemoattractant produced 
by macrophages, lymphocytes, basophils, epithelial 
cells, endothelial cells and (myo)fibroblasts [25], and is 
involved in the pathogenesis of a variety of inflammatory 
lung diseases [4, 26]. In the context of bacterial pneumo-
nia, Ccl2 knockout mice have been shown to exhibit a 
decreased monocytic immune response [27]. In our pre-
vious analyses, we found that CCL2 Tg mice exhibited an 
improved pneumococcal clearance after infection with S. 
pneumoniae, but at the same time developed OP lesions. 
Specific blockade of the CCL2 receptor CCR2 with func-
tion-blocking antibody MC21 resulted in both reduced 
bacterial clearance and abrogation of OP manifestations 
[9]. Therefore, combined CCL2/Ccl2 expression in lungs 
of transgenic mice is most likely associated with mani-
festation of OP lesions in the small airways and adjacent 
alveoli along with a complementary and multifocal accu-
mulation of inflammatory cells.
The fact that the CCL2 transgenic animals without S. 
pneumonia infection did not developed OP, points to 
Fig. 4 Gene expression levels of the Tgfb1/TGFB1 cascade in human OP lesions, compared to controls. TGFB1/Tgfb1, CXCL12/Cxcl12, TIMP1/Timp1, 
TIMP2/Timp2, COL3A1/Col3a1 and MMP2/Mmp2 show an OP lesion-specific overexpression in both human and murine lungs. In contrast, BMP4 
and BMPR1B were upregulated in human OP lesions, compared to controls, while in murine lungs both genes were downregulated. There was no 
significant difference in the expression level of IL6/Il6. Ctrl.—control(s)
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the importance of the infections in the disease’s devel-
opment. On the other hand, infected CCL2 transgenic 
animals developing OP showed significantly higher 
expression of CCL2 than those infected CCL2 animals 
that did not develop OP. Hence, our data suggested a 
direct relationship between S. pneumonia infection, high 
expression of CCL2 and the development of OP.
In OP lesions, increased expression of proinflammatory 
mediators indicates that leukocytes and stromal cells gen-
erate a specific microenvironment, which in turn helps 
to recruit more cells to sites of inflammation. We could 
demonstrate these compartment-specific differences in 
gene expression by analyzing and comparing laser-micro-
dissected OP lesions and adjacent non-remodeled areas 
within the same animals. We found that the molecular 
profile in murine and human OP lesions was character-
ized by increased expression of proinflammatory signal-
ing factors (Cxcl12/Cxcr4 in mice, CXCL12 in humans) 
and profibrotic mediators (murine/human Tgfb1/TGFB1 
and Timps/TIMPs). Cxcl12 is produced and secreted by 
fibroblasts, while its complementary receptor Cxcr4 is 
expressed by leukocytes [10, 11]. In a murine heterotopic 
tracheal transplant model with tracheal obliteration by 
granulation tissue and other murine bleomycin-asso-
ciated fibrosis models, Cxcl12-inhibition resulted in an 
attenuation of fibroblastic trafficking/migration, which 
underlines the importance of the Cxcl12/Cxcr4 axis for 
generating a profibrotic pulmonary microenvironment 
[18, 28, 29]. Profibrotic Thbs1/THBS1, Smads/SMADs 
and Ptk2/PTK2 were expressed in OP lesions and these 
factors can, although not upregulated on the transcript 
level, contribute to an inflammatory microenvironment. 
In human patients with progressive pulmonary fibrosis, 
TGFB1-associated expression of fibroblastic PTK2 has 
been reported [20, 30] and experiments in a bleomycin-
induced pulmonary fibrosis mouse model indicated that 
this kinase is related to fibroblastic proliferation, activa-
tion and collagen production [31].
Tgfb1 as well as Il6 are cytokines which can be pro-
duced both by leukocytes and stroma cells and both can 
induce an aberrant wound healing response resulting in 
(over)activation, migration and proliferation of (myo)
fibroblasts [32–34]. In particular, Tgfb1 also induces the 
differentiation of fibroblast into myofibroblasts, which 
promotes ECM production and collagen accumulation 
[10, 32, 34]. Smad3 is linked to Tgfb1 signaling while 
Smad1 is associated with Bmp signaling pathways [35–
38]. In contrast to Tgfb1, downstream Smad1 and Smad3 
were not increased in murine OP lesions and both Bmp4 
and its receptor Bmpr1b, were downregulated. Similar to 
the regulation in mice, TGFB1 was increased in human 
OP lesions—but in contrast to the murine setting, these 
factors were deregulated in an inverse fashion with 
increased SMADs and BMP4/BMPR1B. Bmp4 is known 
to inhibit fibroblastic activation and proliferation on its 
own, while together with Tgfb1, it further promotes dif-
ferentiation of lung fibroblasts into myofibroblasts [32, 
34, 39]. Therefore, myofibroblastic activation in human 
OP is most likely mediated by the TGFB1/SMAD3 axis, 
as well as by BMP4/SMAD1 signaling, while in mice an 
OP-restricted decrease of murine Bmp4/Bmpr1b could 
contribute to aggregation of myofibroblasts within the 
lesions.
In bronchoalveolar lavage fluids from human patients 
with OP, IL6 was shown to be increased [40], while in 
other studies in lung-transplanted humans, alveolar mac-
rophage-derived IL6 was increased at the time of onset 
of acute rejection, but not in patients who developed 
Table 3 Comparison of  expression levels of  inflammation- 
and fibrosis-associated genes in human and murine OP lesions
Gene Own data















OP organizing pneumonia, ↑ upregulation (green) in OP lesions compared to 
non-remodeled bronchioles of hCCL2 mice without OP manifestation (OP-Ctrl.)/
human controls, → no significant differences in gene expression (gray), ↓ 
downregulation (red) compared to non-remodeled bronchioles of hCCL2 mice 
without OP manifestation (OP-Ctrl.)/human controls
* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001
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chronic lung allograft dysfunction (CLAD) [16]. In our 
analyses of mice and humans, the local expression levels 
of IL6 were comparable in remodeled and non-remodeled 
segments of the lung. This indicates an unspecific reaction 
to bacterial infection, suggesting that IL6 expression was 
in response to infection, but not in an OP-specific man-
ner, which affects all compartments of the lung. How-
ever, the major driver of inflammatory processes within 
the murine and human OP lesions was not Il6/IL6 but 
Tgfb1/TGFB1. Tgfb1 is secreted in the form of an inac-
tive complex which becomes activated by latency-associ-
ated protein (LAP) and Tgfb1/LMP dissociation, which 
in turn can be induced by several factors, such as throm-
bospondins (THBS) and Mmps [35, 41]. Thbs1, as well as 
Mmp inhibitors Timp1 and Timp2 are in turn typically 
associated with Tgfb1-induced fibrotic tissue remodeling 
[32, 41]. Our analyses revealed that Timps/TIMPs were 
increased in murine and human OP lesions alike, which 
was also paralleled by an increased expression of col-
lagens, thus resulting in accumulation of ECM. Matrix 
cleavage enzyme Mmp2 was significantly upregulated in 
human and to a lesser extent murine OP. Since Mmp2/
MMP2 can be inhibited by Timps/TIMPs, accumulation 
of ECM components is increased in both systems. Fur-
thermore, the matricellular profibrotic factor Thbs1 was 
upregulated in murine—but not in human—OP lesions. 
In human BO lesions, THBS1 has been shown to be over-
expressed, which might indicate a different mechanism of 
THBS1-mediated fibrosis in human OP and BO [10].
Conclusions
In summary, lung bacterial infections in the presence of 
high intra-alveolar levels of CCL2 rendered mice suscep-
tible to developing OP lesions. Compartment-specific 
analysis of laser-microdissected lung tissue in a mouse 
model of infection-induced OP revealed that, comple-
mentary to histomorphological changes, OP lesions 
show a characteristic proinflammatory molecular profile 
in mice as well as in humans with OP. The OP micro-
environment typically shows higher levels of Tgfb1 and 
Cxcl12/Cxcr4 signaling factors, profibrotic Thbs1 and 
inhibitors of collagen degradation Timp1/Timp2. Com-
parative gene expression analysis in human and murine 
OP lesions displayed in part similar expression levels, 
notably of TGFB1/Tgfb1, TIMP1/Timp1, TIMP2/Timp2, 
COL3A1/Col3a1, CXCL12/Cxcl12, MMP2/Mmp2 and 
IL6/Il6. Therefore, the currently employed humanized 
mouse model of lung-specific CCL2 overexpression 
shows pathogenomic morphological and molecular fea-
tures of human OP, making this animal model suitable for 
further investigation of fibrotic pulmonary remodeling, 
particularly of OP, in regard to pathogenesis and poten-
tial therapeutic strategies.
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